LiDCO Group Plc 21 April 2008 Press Release 21 April 2008 LiDCO Group Plc ("LiDCO" or the "Company") Launch of new LiDCOrapid Monitor First Sales to Europe and the USA New Market Opportunity LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that its new surgery product, the LiDCOrapid Monitor, has now been released for sale in Europe and the USA. Dr Terry O'Brien, LiDCO's CEO, commented: "I am pleased to announce that the first shipments of our new easy-to-use surgery product - the LiDCOrapid Monitor - are now on the way to customers in the USA and Europe. This follows final regulatory clearance. "This new product opens a much bigger market opportunity for LiDCO. Our successful LiDCOplus monitor is now widely used in Intensive Care Units for high-risk cardiovascular and shock patients. Our new LiDCOrapid monitor is targeted at use in the Operating Theatre, where many more times as many patients are treated. Both products share the favourable attributes of not only reducing complications but also saving costs. "We have had excellent feedback from the pre-launch clinical user group who have been using the LiDCOrapid in major surgery patients in the UK and USA. We also had a very favourable reaction when the product was previewed at two international congresses - the World Congress of Intensive Care, Cape Town, and the ESICM meeting in Brussels. At these meetings alone we took around 500 sales leads. This positive customer response to our new easy-to-use hemodynamic monitor confirms our initial impressions: there is a great appetite for use of the LiDCOrapid in order to reduce surgical complications. I am delighted that our direct sales staff and our growing distributor network can now begin to capitalise on this exciting global market opportunity." The LiDCOrapid Monitor is an ideal new tool for acute care fluid and drug management, facilitating the efficient delivery of goal-directed management (GDM) strategies directly at the point of care in the operating theatre. It incorporates LiDCO's proprietary, patented and clinically validated PulseCO algorithm. The new monitor features many clinical benefits. These enable acute care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being during and after surgery. • Early and rapid warning of change • Clear indication of therapeutic route: fluid or drug • Quantification of hemodynamic response, particularly stroke volume • Permits more effective delivery of fluids - the right amount at the right time • Contributes to reduced morbidity and complications, notably infections • Reduces length of stay • Reduces overall cost of care As previously announced, LiDCO's preliminary results will be disseminated on Thursday, 24 April 2008. An analyst briefing will now be taking place at the offices of Abchurch Communications, LiDCO's new PR advisor, at 100 Cannon Street. London EC4N 6EU at 09:30am. If you are interested in attending the briefing, please contact Abchurch on 020 7398 7700. - ENDS - For more information please contact: LiDCO Group Plc www.LiDCO.co.uk Terry O'Brien, Chief Executive Tel: +44 (0)20 7749 1500 John Rowland, Company Secretary Media enquiries Abchurch Communications www.abchurch-group.com Heather Salmond / Stephanie Cuthbert Tel: +44 (0) 207 398 7718 Stephanie.cuthbert@abchurch-group.com About LiDCO Group Plc LiDCO is a leading supplier of minimally invasive hemodynamic monitoring equipment and disposables. These are used primarily for the management of hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology significantly reduces the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com. The Company's manufacturing facility is in Hoxton, London and its current products are: * LiDCOplus and PulseCO monitors: these computer-based platforms are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume (PPV% and SVV%) * LiDCO disposables: used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner * LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase * LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors * LiDCOrapid : our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care Distribution Network: The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil, South Korea and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors. This information is provided by RNS The company news service from the London Stock Exchange